Skip to main content
Premium Trial:

Request an Annual Quote

ArcticZymes Proteinase

ArcticZymes announced today the release of its first proteinase enzyme. The proteinase is a heat-labile enzyme that is inactivated after use. Gentle inactivation enables broader compatibility in developing kits and products serving the in vitro diagnostic and molecular research market segments,  ArcticZymes said. According to the firm, the new enzyme will allow ArcticZymes to enter the liquid biopsy and sample preparation markets, which it believes will resonate well with IVD companies developing non-invasive tests based on cancer biomarkers. 

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.